BCLI - BrainStorm FDA to discuss regulatory path forward for ALS therapy
2023-11-20 10:57:50 ET
More on BrainStorm Cell Therapeutics
- BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript
- Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
- Brainstorm realigns resources to support NurOwn development
- Brainstorm to pull marketing application for ALS therapy
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
For further details see:
BrainStorm, FDA to discuss regulatory path forward for ALS therapy